Searched for
ABBOTT SHARE PRICE
AI trade moves from chips to electricity: Why 7 power stocks are gaining Wall Street attention with gains up to 86%Wall Street’s AI trade is expanding beyond chipmakers to power producers, grid builders and equipment suppliers as surging data-centre elec...- Abbott Labs shares jump 12% as Q2 sales rise, profit outlook raisedAbbott Laboratories shares surged 12% after the healthcare company reported strong second-quarter sales, raised its full-year earnings outl...
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 24%When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...
- Human urine becomes option for farmers in fertilizer supply crunchFrom chicken muck to human urine-based products and microbial solutions, growers are improvising to maintain crop yields. This shift, while...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Buy Abbott India, target price Rs 31,420: Axis SecuritiesAxis Securities recommends buying Abbott India Ltd. with a target price of Rs 31,420. The pharmaceutical company reported a 24% rise in fou...
- Stock Radar: Abbott India records fresh high in August but pares gains; should you buy the dip?The pharma stock with a market capitalization of over Rs 50,000 crore on the BSE hit a record high of Rs 24,682 on 4 August 2023, after it ...
- Chart Check: This pharma stock hits fresh 52-week high in December; likely to scale Rs 24,000For more than a decade, the stock has been taking support at a rising moving average followed by a breach of the intermediate falling trend...
- Abbott India Q4 results: Net profit up 39% at Rs 211 croreRevenue from operations rose to Rs 1,255 crore in the period under review as compared with Rs 1,096 crore in the year-ago period, it added.
- Abbott India Q2 results: Net profit up 6% to Rs 192 croreRevenue from operations stood at Rs 1,222.06 crore for the quarter under consideration.
- Abbott India Q2 results: Net profit up 1% to Rs 181 croreRevenue from operations remained flat at Rs 1,054.85 crore during the quarter under review as compared with Rs 1,054.80 crore in the year-a...
- Outperformer rating for Abbott India, target price Rs 18,130: CLSAThe lockdown will limit near-term growth, said CLSA, cutting FY21-FY22 EPS estimates by 9-11 per cent.
- Buy Abbott India, Rs 18,069: ICICI SecuritiesAbbott India is one of the brokerages top picks in the pharma sector.
- CLSA initiates coverage on Abbott India with buy ratingShares of Abbott India ended up 0.75 per cent at Rs 11,763 on Wednesday.
- Share market update: 10 stocks hit 52-week highs on NSEBenchmark NSE Nifty index was trading 3.85 points down at 10,794.05.
- Abbott to buy Latin American drugmaker CFR in $2.9 billion dealAbbott Lab would acquire Chile's CFR Pharma SA in a two-part, $2.9 bn deal, to double its branded generic drugs portfolio & expand in fast-...
- Abbott Laboratories set to consolidate India operationsThe $39-bn pharma giant Abbott Labs will consolidate India operations under a new leadership, as part of a plan to tap operational synergie...
- Abbott yet to reap benefits of Piramal buyThe purchase of Piramal Healthcare's domestic formulations biz by Abbott Lab has changed little on the ground for the foreign company even ...
- Abbott India to buyback shares worth Rs 50.24 crDrug maker Abbott India on Friday said it will buyback shares worth up to Rs 50.24 cr from its shareholders at a price of Rs 630 per share.
Load More
